Business
BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025
LUND, SE / ACCESS Newswire / November 3, 2025 /BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...
About this update from Bioinvent International Ab
[{"type":"text","content":"LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will present new data from the safety run-in portion of its ongoing trial evaluating BI-1206 in combination with rituximab and Calquence ® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) in a poster at the upcoming 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida.","length":647,"tagName":"p"},{"type":"text","content":"Abstract data (as of August 4, 2025) published in the November supplemental issue of Blood demonstrates that the triple combination regimen is safe and well-tolerated, with encouraging efficacy data. Due to the current number of patients, it is important to note that the response rates are still fluctuating, and the data set will become more robust as patient numbers increase. A more recent data set will be included in the poster at ASH to be presented on December 8, 2025.","length":477,"tagName":"p"},{"type":"text","content":""We are very pleased with the progress of the trial and encouraged by both the safety and efficacy signals emerging from the safety run-in. We are delighted that ASH has accepted our data for a poster presentation" said Martin Welschof, Chief Executive Officer of BioInvent. "The data show that the triple combination is well-tolerated and the overall response rate is well on track to meet our goals. This would provide a strong foundation for advancing into the next phase, where we look forward to further evaluating the potential of this regimen to transform outcomes for patients and improve the standard of care."","length":639,"tagName":"p"},{"type":"text","content":"Poster presentation details:","length":28,"tagName":"p"},{"type":"text","content":"Title: Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patientsDate and Time: December 8, 2025, 6:00 PM - 8:00 PM ETSession name: 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster IIILead Author: Laura Fogliatto...